Robert H. Lurie Comprehensive Cancer Center of Northwestern University has been awarded a new, five-year $11.5 million Specialized Program of Research Excellence grant to advance translational research and improve outcomes for patients with brain cancer.
Last week, FDA granted accelerated approval to Replimune Group Inc. for it’s biologic, RP1 (vusolimogene oderparepvec), following the FDA Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
